 Though the major indices posted a strong recovery effort on Wednesday, late-stage clinical biopharmaceutical firm Geron NASDAQ: GERN soared above most public players. Following positive top-line results for its blood cancer therapeutic, GERN stock jumped 50 before settling around 34 up in the early afternoon. 